Breast cancer survivors may test positive for pathogenic germline variants 10 years after their original diagnosis. Germline genetic testing may be an important tool for managing care.
Improved understanding of potential risk factors associated with weight gain will allow identification of at-risk patients and intervention for improved outcomes.
The VA CARES program provides coordinated cancer care for veterans prescribed oral antineoplastic therapies who may lack access to comprehensive medication management resources.
Alpelisib plus fulvestrant combination therapy improves progression-free survival while maintaining effectiveness in patients with HR-positive/HER2-negative advanced breast cancer in a French early access study.
Metabolic syndrome is associated with poor prognosis in patients with breast cancer. Identifying potential risk factors for metabolic syndrome may improve outcomes in these women.
